Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849659 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL1325867 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4676912 | 0.98 | ALDH1A1 (0.80) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6993232 | 0.98 | ALDH1A1 (0.80) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL30995662 | 0.91 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL725878 | 0.89 | ALDH1A1 (0.72) | ALDH1A1CYP1A2CYP2D6KMT2AANPEP | |
| SCHEMBL15087836 | 0.89 | ALDH1A1 (0.97) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL15090295 | 0.89 | ALDH1A1 (0.97) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL6262911 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6KMT2ADNM1 | |
| SCHEMBL15325585 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542964-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004029019-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| WO-2026099455-A1 | DIHYDROPYRROLOPYRIMIDINONE COMPOUNDS AS TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| CN-101384603-B | Novel, acyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases | BAYER SCHERING PHARMA AG | 2012-08-01 | — | — | CN | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| CN-101384603-A | Novel, acyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-03-11 | — | — | CN | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966217-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1542964-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004029019-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | ALDH1A1 3236/4885CYP1A2 4432/4885CYP2D6 4223/4885 |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | ALDH1A1 318/4885CYP1A2 175/4885CYP2D6 109/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | ALDH1A1 3236/4885CYP1A2 4432/4885CYP2D6 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.